Sugammadex Reversal of Neuromuscular Blockade and Postoperative Bleeding

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02939430

Acronym

Suga_bleeding

Enrollment

Registered

2016-10-20

Start date

2016-11-30

Completion date

2017-11-30

Last updated

2017-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Coagulation Tests ( INR, APTT)

Brief summary

Sugammadex is new drug that is used for reversal of rocuronium induced muscle relaxation. benefits of reversal of neuromuscular blockade appears to be of great value in living donor liver transplant recipients. However, Few Clinical reports have investigated the anticoagulant effect of sugammadex. In this study, effects of sugammadex on bleeding profile of living donor liver transplantation will be investigated.

Interventions

DRUGSugammadex intravenous

Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation

DRUGIntravenous neostigmine and atropine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

* all candidates for living donor liver transplantation

Exclusion criteria

* massive intraoperative bleeding manifestations of early graft dysfunction

Design outcomes

Primary

Measure	Time frame
activated partial thromboplastin tile in seconds	30 min

Secondary

Measure	Time frame
international normalized ratio in second	30 min

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026